Experience of using benralizumab in the treatment of patients with severe asthma in the clinical practice of pulmonologists in Saint-Petersburg

The accumulation of clinical experience in the use of biologic therapy in patients with severe bronchial asthma (SBA) in real-world clinical practice with the possible identification of additional, previously undescribed clinical outcomes is of practical interest.

The aim. To present the results of an observational study of using benralizumab in SBA in real clinical practice of pulmonologists in Saint-Petersburg.

Methods. We present the results of more than 1 year of follow-up of 18 patients with eosinophilic SBA (12 women, 6 men, age from 28 to 74, average age 55.0 ± 11.9 years). The patients received benralizumab in addition to standard treatment. Clinical, laboratory, and functional examination of the patients were performed, the frequency of exacerbations and additional clinical effects were assessed. Results. It has been shown that the inclusion of benralizumab in complex therapy resulted in a significant improvement in disease control, improved bronchial conduction, a significant decrease in blood eosinophilia, and a reduction in the number of exacerbations. A clinical example is given that indicates a stabilizing effect of this therapy on the course of recurrent nasal polyposis with an initially aggressive course (intracranial polyp growth).

Conclusion. The possibility of significant improvement in the control of SBA with the use of biological therapy has been confirmed in real clinical practice. At the same time, data have been obtained that will allow expanding the indications for the use of benralizumab in the future.

1. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. [Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation]. Pul’monologiya. 2018; 28 (3): 341– 358. DOI: 10.18093/0869-0189-2018-28-3-341-358 (in Russian).

2. Knyazheskaya N.P., Anaev E.Kh., Kameleva A.A. et al. [Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids]. Meditsinskiy Sovet. 2020; (17): 9–16. DOI: 10.21518/2079-701X-2020-17-9-16 (in Russian).

3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022 Report. Available at: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL22-07-01-WMS.pdf [Accessed: May 17, 2022].

4. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N. et al. [Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype]. Pul’monologiya. 2020; 30 (2): 227–244. DOI: 10.18093/0869-0189-2020-30-2-227-244 (in Russian).

5. [Instructions for the medical use of the drug Fasenra]. Available at: https://www.astrazeneca.ru/content/dam/az-ru/downloads/preparations/Fasenra-Pen-Leaflet-RU-V1.pdf (in Russian).

6. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.

7. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.

8. Bachert C., Han J.K., Desrosiers M.Y. et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2022; 149 (4): 1309–1317.e12. DOI: 10.1016/j.jaci.2021.08.030.

9. Korn S., Bourdin A., Chupp G. et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J. Allergy Clin. Immunol. Pract. 2021; 9 (12): 4381–4392.e4. DOI: 10.1016/j.jaip.2021.07.058.

10. Menzies-Gow A., Gurnell M., Heaney L.G. et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir. Med. 2022; 10 (1): 47–58. DOI: 10.1016/S2213-2600(21)00352-0.

11. Chung Y., Katial R., Mu F. et al. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 study. Ann. Allergy Asthma Immunol. 2022; 128 (6): 669–676.e6. DOI: 10.1016/j.anai.2022.02.017.

12. Pelaia C., Busceti M.T., Vatrella A. et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm. Pharmacol. Ther. 2019; 58: 101830. DOI: 10.1016/j.pupt.2019.101830.

13. Kavanagh J.E., Hearn A.P., Dhariwal J. et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021; 159 (2): 496–506. DOI: 10.1016/j.chest.2020.08.2083.

14. Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448–2458. DOI: 10.1056/NEJMoa1703501.